首页> 外文期刊>慢性疾病与转化医学(英文) >Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
【24h】

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai

机译:新型口服抗凝药是否能改善非瓣膜性房颤相关性卒中的抗凝作用:一项在上海的住院登记研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective:To summarize the use rate,safety,efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention,and reasons for not using dabigatran etexilate (DE) in Shanghai,China.Methods:Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database.Use rate of antithrombofics and reasons for not using DE were extracted during follow-up.Patients' baseline characteristics,recurrent ischemic stroke/TIA events and bleeding complications were analyzed.Patients:From April 2012 to August 2014,110 inpatients with NVAF-associated stroke were studied in our hospital.NVAF was diagnosed by 12-lead electrocardiogram,24 h Holter and echocardiography.Results:Before introduction of DE (April 2013),use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38)respectively; after that,use rates of warfarin,DE,and antiplatelets were 20.8% (15/72),12.5% (9/72),and 43.1% (31/72).The DE did not improve use of anticoagulants (P =0.639).There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group,10 (18.5%) in the antiplatelet group,and seven (20.0%) in the anticoagulants group (P =0.570).Furthermore,recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%,P =1.000).The most common reason for not using DE was financial concerns (61.0%),followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%).Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs.No bleeding event occurred in the other groups.Only one patient had side effects (dyspepsia and gastroesophageal reflux)from DE.Conclusion:The use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance.
机译:目的:总结抗栓药在中风/短暂性脑缺血发作(TIA)预防中的使用率,安全性,有效性以及在上海不使用达比加群酯(DE)的原因。方法:非瓣膜性房颤(NVAF)-前瞻性地将相关的卒中患者注册为电子数据库。在随访中提取抗血栓形成剂的使用率和不使用DE的原因。分析患者的基线特征,反复缺血性卒中/ TIA事件和出血并发症。患者:2012年4月起截止2014年8月,我院共对110例NVAF相关性卒中患者进行了研究。通过12导联心电图,24h动态心电图和超声心动图对NVAF进行诊断。 28.9%(11/38)和60.5%(23/38);此后,华法林,DE和抗血小板剂的使用率分别为20.8%(15/72),12.5%(9/72)和43.1%(31/72)。DE不能改善抗凝剂的使用(P = 0.639)截至2015年10月,有19例(17.3%)复发性缺血性中风事件;非使用组中有两个(9.5%),抗血小板组中有10(18.5%),抗凝剂组中有七个(20.0%)(P = 0.570)。此外,DE组之间的复发率相似(20.0 %)和华法林组(20.0%,P = 1.000)。不使用DE的最常见原因是财务方面的担忧(61.0%),其次是购买不便(14.0%)和出血方面的担忧(11.0%)。两名患者使用华法林发现粪便潜血,因此停止使用华法林并开始使用抗血小板药物,其他组均未发生出血事件,只有一名患者因DE出现副作用(消化不良和胃食管反流)。结论:DE的使用率或上海的华法林水平低;在上海,DE未能改善NVAF患者的抗凝治疗,这主要是因为DE尚未纳入健康保险。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号